Employing FreeMind Group‘s excellence alongside Daewoong Pharma’s leadership position
FMI combines an exclusive dataset, life science managerial experience, and expertise with a solid track record in investments
Combining strengths. Making investments.
FMI provides not only direct formula-backed equity investments, but also a myriad of pharma deal-making opportunities to its investees such as access to the Asian market, co-development and partnerships.
A new Platform for Global Life Science Investments
Data driven investment model
Exclusive database of 500+ life science companies
~100 new companies added annually
Geographic breakdown: US: 60% / EU: 30% / Israel, Australia, Canada: 10%
Statistically significant correlation with business performance
Scientific vetting by world’s top scientists
Diligent review of overall management skills and ethics
Proprietary de-risking formula identifies potential scientific and business success
+50% of identified companies exit (IPO/M&A) within 5 years
2255
Total pipeline projects in FMI dataset
568
Total companies in FMI dataset
183
FMI top candidate companies
FreeMind Exclusive Investments Database
4 year rolling data regularly updated with ~100+ new candidates annually
Geographical Split
Global deal flow with an emphasis on the US market allows FMI access to the top invest opportunities globally.
From Discovery to the Market
FMI reviews companies at all stages of development with a focus on pre-clinical as well as clinical stage programs.
Across all Scientific Fields of Research
Covering solutions addressing most human health conditions with therapeutics and medical devices (non-therapeutics).
Proprietary Investment Formula
De-risking life science investments at the intersection of the FreeMind organizational score, federal scientific score and business potential assessed by a detailed due diligence process
Organizational Quality Quantified
Single weighted score given by FreeMind Group using its proprietary analysis, evaluating both ‘hard’ and ‘soft’ attributes, and followed over time
Scientific Excellence – Quantified
Rigorous scientific due diligence by 5,000 leading KOLs in their respective field of research. 220 review groups with 20-30 experts in each group
Due Diligence
Rigorous due diligence focused on industry impact, appeal and exit potential